Stem definition | Drug id | CAS RN |
---|---|---|
2597 | 91161-71-6 |
Dose | Unit | Route |
---|---|---|
0.25 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 92.64 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 30, 1992 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ageusia | 358.71 | 15.80 | 123 | 10858 | 11460 | 50582683 |
Acute generalised exanthematous pustulosis | 204.98 | 15.80 | 76 | 10905 | 8862 | 50585281 |
Subacute cutaneous lupus erythematosus | 182.83 | 15.80 | 50 | 10931 | 2165 | 50591978 |
Dysgeusia | 148.60 | 15.80 | 97 | 10884 | 38819 | 50555324 |
Rash pustular | 105.55 | 15.80 | 43 | 10938 | 6438 | 50587705 |
Gamma-glutamyltransferase increased | 99.00 | 15.80 | 68 | 10913 | 29555 | 50564588 |
Pruritus | 96.98 | 15.80 | 199 | 10782 | 283369 | 50310774 |
Aspartate aminotransferase increased | 91.33 | 15.80 | 98 | 10883 | 77900 | 50516243 |
Cutaneous lupus erythematosus | 87.76 | 15.80 | 29 | 10952 | 2402 | 50591741 |
Toxic skin eruption | 82.87 | 15.80 | 43 | 10938 | 11208 | 50582935 |
Erythema multiforme | 82.59 | 15.80 | 40 | 10941 | 9010 | 50585133 |
Blood alkaline phosphatase increased | 82.51 | 15.80 | 67 | 10914 | 37459 | 50556684 |
Alanine aminotransferase increased | 74.87 | 15.80 | 94 | 10887 | 88265 | 50505878 |
Skin exfoliation | 73.86 | 15.80 | 60 | 10921 | 33552 | 50560591 |
Pathogen resistance | 73.44 | 15.80 | 32 | 10949 | 5657 | 50588486 |
Chromaturia | 69.81 | 15.80 | 42 | 10939 | 14548 | 50579595 |
Rash | 63.14 | 15.80 | 223 | 10758 | 437248 | 50156895 |
Somatic delusion | 62.05 | 15.80 | 16 | 10965 | 550 | 50593593 |
Jaundice | 61.94 | 15.80 | 49 | 10932 | 26380 | 50567763 |
Erythema | 59.92 | 15.80 | 111 | 10870 | 146303 | 50447840 |
Urticaria | 53.97 | 15.80 | 99 | 10882 | 129462 | 50464681 |
Hepatic function abnormal | 50.96 | 15.80 | 48 | 10933 | 32633 | 50561510 |
Rash erythematous | 48.34 | 15.80 | 48 | 10933 | 34804 | 50559339 |
Anosmia | 43.96 | 15.80 | 20 | 10961 | 3911 | 50590232 |
Lip swelling | 43.76 | 15.80 | 39 | 10942 | 24697 | 50569446 |
Rash maculo-papular | 41.28 | 15.80 | 39 | 10942 | 26602 | 50567541 |
Skin lesion | 41.18 | 15.80 | 39 | 10942 | 26688 | 50567455 |
Blood lactate dehydrogenase increased | 41.03 | 15.80 | 34 | 10947 | 19528 | 50574615 |
Hepatitis | 39.39 | 15.80 | 41 | 10940 | 31412 | 50562731 |
Blood bilirubin increased | 38.76 | 15.80 | 41 | 10940 | 31997 | 50562146 |
Liver disorder | 37.04 | 15.80 | 43 | 10938 | 37179 | 50556964 |
Photosensitivity reaction | 34.75 | 15.80 | 26 | 10955 | 12885 | 50581258 |
Pustular psoriasis | 34.53 | 15.80 | 17 | 10964 | 3964 | 50590179 |
Drug resistance | 33.71 | 15.80 | 30 | 10951 | 18959 | 50575184 |
Oral discomfort | 33.06 | 15.80 | 21 | 10960 | 7996 | 50586147 |
Abnormal faeces | 30.78 | 15.80 | 16 | 10965 | 4180 | 50589963 |
Dermatitis bullous | 30.11 | 15.80 | 19 | 10962 | 7154 | 50586989 |
Drug eruption | 29.96 | 15.80 | 31 | 10950 | 23575 | 50570568 |
Gastrointestinal motility disorder | 29.70 | 15.80 | 16 | 10965 | 4493 | 50589650 |
Drug intolerance | 29.20 | 15.80 | 6 | 10975 | 219098 | 50375045 |
Dermatitis exfoliative | 27.73 | 15.80 | 16 | 10965 | 5126 | 50589017 |
Weight decreased | 27.73 | 15.80 | 108 | 10873 | 221137 | 50373006 |
Urine odour abnormal | 27.08 | 15.80 | 16 | 10965 | 5357 | 50588786 |
Skin oedema | 26.92 | 15.80 | 9 | 10972 | 772 | 50593371 |
Rash papular | 26.62 | 15.80 | 22 | 10959 | 12582 | 50581561 |
Bilirubin conjugated increased | 26.02 | 15.80 | 12 | 10969 | 2420 | 50591723 |
Drug-induced liver injury | 25.54 | 15.80 | 31 | 10950 | 28064 | 50566079 |
Red blood cell count decreased | 25.49 | 15.80 | 34 | 10947 | 33801 | 50560342 |
Hepatitis cholestatic | 25.17 | 15.80 | 16 | 10965 | 6101 | 50588042 |
Drug interaction | 24.65 | 15.80 | 97 | 10884 | 199524 | 50394619 |
Rash pruritic | 24.37 | 15.80 | 40 | 10941 | 47806 | 50546337 |
Blood creatine phosphokinase increased | 23.82 | 15.80 | 29 | 10952 | 26338 | 50567805 |
Face oedema | 23.68 | 15.80 | 24 | 10957 | 17815 | 50576328 |
Erythema nodosum | 23.36 | 15.80 | 13 | 10968 | 3890 | 50590253 |
Systemic lupus erythematosus rash | 23.07 | 15.80 | 10 | 10971 | 1745 | 50592398 |
Drug ineffective | 22.94 | 15.80 | 96 | 10885 | 819237 | 49774906 |
Rash papulosquamous | 22.37 | 15.80 | 5 | 10976 | 92 | 50594051 |
Antinuclear antibody positive | 22.37 | 15.80 | 15 | 10966 | 6257 | 50587886 |
Tinea infection | 21.87 | 15.80 | 8 | 10973 | 895 | 50593248 |
Off label use | 21.71 | 15.80 | 44 | 10937 | 474382 | 50119761 |
Musculoskeletal discomfort | 21.54 | 15.80 | 21 | 10960 | 14877 | 50579266 |
Death | 20.81 | 15.80 | 24 | 10957 | 325355 | 50268788 |
Rash macular | 20.40 | 15.80 | 23 | 10958 | 19254 | 50574889 |
Hypotension | 20.37 | 15.80 | 13 | 10968 | 235456 | 50358687 |
Respiratory gas exchange disorder | 20.36 | 15.80 | 6 | 10975 | 340 | 50593803 |
Onychomycosis | 20.28 | 15.80 | 13 | 10968 | 5029 | 50589114 |
Pythium insidiosum infection | 20.23 | 15.80 | 3 | 10978 | 3 | 50594140 |
Blister | 20.23 | 15.80 | 52 | 10929 | 85366 | 50508777 |
Maternal exposure during pregnancy | 20.03 | 15.80 | 5 | 10976 | 159773 | 50434370 |
Decreased appetite | 19.66 | 15.80 | 91 | 10890 | 200832 | 50393311 |
Eosinophilia | 19.31 | 15.80 | 22 | 10959 | 18630 | 50575513 |
Abortion induced | 19.09 | 15.80 | 16 | 10965 | 9328 | 50584815 |
Swollen tongue | 18.90 | 15.80 | 27 | 10954 | 28603 | 50565540 |
Cheilitis | 18.85 | 15.80 | 11 | 10970 | 3599 | 50590544 |
Liver function test abnormal | 18.57 | 15.80 | 34 | 10947 | 44305 | 50549838 |
Hepatitis toxic | 18.57 | 15.80 | 10 | 10971 | 2806 | 50591337 |
Toxicity to various agents | 18.01 | 15.80 | 12 | 10969 | 212487 | 50381656 |
Pityriasis rosea | 17.93 | 15.80 | 4 | 10977 | 73 | 50594070 |
Therapeutic product effect decreased | 17.56 | 15.80 | 4 | 10977 | 136046 | 50458097 |
Fundoscopy abnormal | 17.29 | 15.80 | 3 | 10978 | 13 | 50594130 |
Hepatic cytolysis | 16.81 | 15.80 | 14 | 10967 | 8089 | 50586054 |
Pneumonia respiratory syncytial viral | 16.65 | 15.80 | 6 | 10975 | 644 | 50593499 |
Fungal skin infection | 15.88 | 15.80 | 10 | 10971 | 3749 | 50590394 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 189.65 | 14.12 | 82 | 11258 | 8034 | 29555153 |
Aspartate aminotransferase increased | 120.89 | 14.12 | 131 | 11209 | 59594 | 29503593 |
Gamma-glutamyltransferase increased | 107.42 | 14.12 | 86 | 11254 | 26651 | 29536536 |
Drug resistance | 96.71 | 14.12 | 74 | 11266 | 21466 | 29541721 |
Alanine aminotransferase increased | 96.34 | 14.12 | 127 | 11213 | 70817 | 29492370 |
Ageusia | 92.95 | 14.12 | 52 | 11288 | 8886 | 29554301 |
Chromaturia | 80.51 | 14.12 | 54 | 11286 | 12748 | 29550439 |
Jaundice | 76.91 | 14.12 | 74 | 11266 | 29222 | 29533965 |
Blood alkaline phosphatase increased | 75.04 | 14.12 | 72 | 11268 | 28334 | 29534853 |
Acute generalised exanthematous pustulosis | 73.50 | 14.12 | 38 | 11302 | 5545 | 29557642 |
Blood creatine phosphokinase increased | 71.61 | 14.12 | 83 | 11257 | 40561 | 29522626 |
Symmetrical drug-related intertriginous and flexural exanthema | 57.10 | 14.12 | 14 | 11326 | 215 | 29562972 |
Pruritus | 52.54 | 14.12 | 129 | 11211 | 116720 | 29446467 |
Diaphragmatic spasm | 51.40 | 14.12 | 11 | 11329 | 88 | 29563099 |
Faecal volume decreased | 49.76 | 14.12 | 11 | 11329 | 104 | 29563083 |
Onychomycosis | 48.68 | 14.12 | 21 | 11319 | 2041 | 29561146 |
Death | 47.74 | 14.12 | 37 | 11303 | 342047 | 29221140 |
Liver disorder | 46.08 | 14.12 | 55 | 11285 | 27694 | 29535493 |
Rash | 45.71 | 14.12 | 168 | 11172 | 189651 | 29373536 |
Rash pustular | 45.27 | 14.12 | 26 | 11314 | 4665 | 29558522 |
Blood lactate dehydrogenase increased | 43.87 | 14.12 | 45 | 11295 | 19164 | 29544023 |
Liver function test abnormal | 42.66 | 14.12 | 54 | 11286 | 28864 | 29534323 |
Blood bilirubin increased | 38.88 | 14.12 | 56 | 11284 | 33837 | 29529350 |
Skin exfoliation | 37.78 | 14.12 | 45 | 11295 | 22600 | 29540587 |
Hypotension | 37.28 | 14.12 | 14 | 11326 | 194340 | 29368847 |
Rash erythematous | 36.22 | 14.12 | 43 | 11297 | 21519 | 29541668 |
Swelling of eyelid | 35.81 | 14.12 | 12 | 11328 | 582 | 29562605 |
Epstein-Barr virus antibody positive | 34.94 | 14.12 | 10 | 11330 | 285 | 29562902 |
Impetigo | 34.18 | 14.12 | 13 | 11327 | 912 | 29562275 |
Hepatic function abnormal | 34.02 | 14.12 | 57 | 11283 | 39202 | 29523985 |
Erythema nodosum | 33.88 | 14.12 | 13 | 11327 | 934 | 29562253 |
Treatment failure | 33.85 | 14.12 | 55 | 11285 | 36884 | 29526303 |
Hepatic lesion | 31.85 | 14.12 | 18 | 11322 | 3132 | 29560055 |
Toxicity to various agents | 30.88 | 14.12 | 14 | 11326 | 173647 | 29389540 |
Erythema | 28.30 | 14.12 | 78 | 11262 | 75528 | 29487659 |
Eczema | 27.33 | 14.12 | 30 | 11310 | 13796 | 29549391 |
Erythema multiforme | 27.14 | 14.12 | 23 | 11317 | 7694 | 29555493 |
Drug-induced liver injury | 26.63 | 14.12 | 37 | 11303 | 21618 | 29541569 |
Rosacea | 26.24 | 14.12 | 11 | 11329 | 996 | 29562191 |
Cutaneous lupus erythematosus | 26.07 | 14.12 | 10 | 11330 | 718 | 29562469 |
Tongue discomfort | 25.78 | 14.12 | 9 | 11331 | 494 | 29562693 |
Off label use | 23.74 | 14.12 | 50 | 11290 | 300750 | 29262437 |
Antinuclear antibody positive | 23.30 | 14.12 | 11 | 11329 | 1319 | 29561868 |
Dysgeusia | 22.47 | 14.12 | 35 | 11305 | 22639 | 29540548 |
Deficiency of bile secretion | 22.46 | 14.12 | 4 | 11336 | 10 | 29563177 |
Hairy cell leukaemia | 21.93 | 14.12 | 5 | 11335 | 55 | 29563132 |
Scedosporium infection | 21.89 | 14.12 | 9 | 11331 | 776 | 29562411 |
Choluria | 21.79 | 14.12 | 6 | 11334 | 148 | 29563039 |
Erythrodermic psoriasis | 21.72 | 14.12 | 9 | 11331 | 791 | 29562396 |
Cholestasis | 21.58 | 14.12 | 35 | 11305 | 23427 | 29539760 |
Hepatitis cholestatic | 21.13 | 14.12 | 19 | 11321 | 6874 | 29556313 |
Myoglobin urine present | 21.00 | 14.12 | 6 | 11334 | 170 | 29563017 |
Myalgia | 20.75 | 14.12 | 69 | 11271 | 73950 | 29489237 |
Blister | 20.11 | 14.12 | 31 | 11309 | 19875 | 29543312 |
Urticaria | 20.05 | 14.12 | 56 | 11284 | 54604 | 29508583 |
Skin warm | 19.81 | 14.12 | 11 | 11329 | 1849 | 29561338 |
Biliary obstruction | 19.68 | 14.12 | 12 | 11328 | 2402 | 29560785 |
Lymphocyte stimulation test positive | 19.42 | 14.12 | 8 | 11332 | 693 | 29562494 |
Rhabdomyolysis | 19.15 | 14.12 | 59 | 11281 | 60749 | 29502438 |
Dermatitis exfoliative | 18.31 | 14.12 | 17 | 11323 | 6408 | 29556779 |
Completed suicide | 18.13 | 14.12 | 6 | 11334 | 90240 | 29472947 |
Hodgkin's disease | 17.92 | 14.12 | 8 | 11332 | 844 | 29562343 |
Discomfort | 17.81 | 14.12 | 25 | 11315 | 14738 | 29548449 |
Dermatitis contact | 17.32 | 14.12 | 12 | 11328 | 2980 | 29560207 |
Dermatitis | 17.31 | 14.12 | 18 | 11322 | 7780 | 29555407 |
Benign breast neoplasm | 16.99 | 14.12 | 3 | 11337 | 7 | 29563180 |
Neutrophil percentage decreased | 16.89 | 14.12 | 6 | 11334 | 347 | 29562840 |
Product dispensing error | 16.59 | 14.12 | 15 | 11325 | 5465 | 29557722 |
Pneumonia | 16.58 | 14.12 | 65 | 11275 | 320107 | 29243080 |
Product substitution issue | 16.58 | 14.12 | 19 | 11321 | 9153 | 29554034 |
Pityriasis rosea | 16.46 | 14.12 | 4 | 11336 | 59 | 29563128 |
Vitamin E deficiency | 16.45 | 14.12 | 3 | 11337 | 9 | 29563178 |
Malaise | 16.40 | 14.12 | 111 | 11229 | 159491 | 29403696 |
Eyelid pain | 16.34 | 14.12 | 4 | 11336 | 61 | 29563126 |
Periorbital oedema | 16.22 | 14.12 | 12 | 11328 | 3303 | 29559884 |
Intertrigo | 15.94 | 14.12 | 5 | 11335 | 196 | 29562991 |
Chronic spontaneous urticaria | 15.72 | 14.12 | 4 | 11336 | 72 | 29563115 |
Drug eruption | 15.42 | 14.12 | 25 | 11315 | 16716 | 29546471 |
Hepatocellular carcinoma | 15.18 | 14.12 | 16 | 11324 | 7022 | 29556165 |
Nail discolouration | 15.17 | 14.12 | 7 | 11333 | 797 | 29562390 |
Neuropsychiatric symptoms | 14.92 | 14.12 | 6 | 11334 | 488 | 29562699 |
Skin plaque | 14.87 | 14.12 | 12 | 11328 | 3750 | 29559437 |
Skin lesion | 14.81 | 14.12 | 26 | 11314 | 18546 | 29544641 |
Hepatic enzyme increased | 14.80 | 14.12 | 37 | 11303 | 33762 | 29529425 |
Needle issue | 14.54 | 14.12 | 13 | 11327 | 4670 | 29558517 |
Trichophytosis | 14.42 | 14.12 | 5 | 11335 | 269 | 29562918 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ageusia | 315.21 | 12.82 | 128 | 19288 | 13685 | 64465631 |
Pathogen resistance | 261.60 | 12.82 | 109 | 19307 | 12434 | 64466882 |
Acute generalised exanthematous pustulosis | 227.08 | 12.82 | 102 | 19314 | 13956 | 64465360 |
Aspartate aminotransferase increased | 165.77 | 12.82 | 192 | 19224 | 119596 | 64359720 |
Subacute cutaneous lupus erythematosus | 163.37 | 12.82 | 53 | 19363 | 2972 | 64476344 |
Gamma-glutamyltransferase increased | 154.02 | 12.82 | 123 | 19293 | 48387 | 64430929 |
Chromaturia | 141.65 | 12.82 | 87 | 19329 | 22524 | 64456792 |
Alanine aminotransferase increased | 139.87 | 12.82 | 190 | 19226 | 138841 | 64340475 |
Rash pustular | 132.39 | 12.82 | 63 | 19353 | 9822 | 64469494 |
Drug resistance | 131.04 | 12.82 | 98 | 19318 | 35004 | 64444312 |
Blood alkaline phosphatase increased | 122.43 | 12.82 | 115 | 19301 | 56164 | 64423152 |
Pruritus | 118.24 | 12.82 | 278 | 19138 | 312122 | 64167194 |
Jaundice | 116.95 | 12.82 | 105 | 19311 | 48407 | 64430909 |
Dysgeusia | 98.24 | 12.82 | 94 | 19322 | 46953 | 64432363 |
Skin exfoliation | 94.33 | 12.82 | 90 | 19326 | 44795 | 64434521 |
Cutaneous lupus erythematosus | 94.01 | 12.82 | 34 | 19382 | 2648 | 64476668 |
Rash | 91.38 | 12.82 | 324 | 19092 | 458225 | 64021091 |
Blood creatine phosphokinase increased | 87.91 | 12.82 | 98 | 19318 | 58460 | 64420856 |
Rash erythematous | 81.04 | 12.82 | 86 | 19330 | 48547 | 64430769 |
Erythema multiforme | 79.89 | 12.82 | 53 | 19363 | 15648 | 64463668 |
Toxic skin eruption | 79.08 | 12.82 | 57 | 19359 | 19227 | 64460089 |
Erythema | 67.92 | 12.82 | 164 | 19252 | 186906 | 64292410 |
Blood lactate dehydrogenase increased | 65.11 | 12.82 | 64 | 19352 | 33014 | 64446302 |
Somatic delusion | 62.53 | 12.82 | 18 | 19398 | 672 | 64478644 |
Hepatic function abnormal | 60.22 | 12.82 | 85 | 19331 | 64228 | 64415088 |
Blood bilirubin increased | 58.29 | 12.82 | 79 | 19337 | 57474 | 64421842 |
Hypotension | 56.58 | 12.82 | 22 | 19394 | 380952 | 64098364 |
Urticaria | 56.53 | 12.82 | 132 | 19284 | 147185 | 64332131 |
Liver function test abnormal | 54.86 | 12.82 | 78 | 19338 | 59323 | 64419993 |
Diaphragmatic spasm | 53.84 | 12.82 | 11 | 19405 | 90 | 64479226 |
Liver disorder | 53.67 | 12.82 | 73 | 19343 | 53278 | 64426038 |
Symmetrical drug-related intertriginous and flexural exanthema | 50.97 | 12.82 | 15 | 19401 | 606 | 64478710 |
Toxicity to various agents | 50.75 | 12.82 | 23 | 19393 | 363490 | 64115826 |
Faecal volume decreased | 48.93 | 12.82 | 11 | 19405 | 147 | 64479169 |
Onychomycosis | 48.66 | 12.82 | 26 | 19390 | 5170 | 64474146 |
Completed suicide | 47.13 | 12.82 | 6 | 19410 | 224408 | 64254908 |
Skin lesion | 46.26 | 12.82 | 56 | 19360 | 36426 | 64442890 |
Death | 43.28 | 12.82 | 49 | 19367 | 482656 | 63996660 |
Pustular psoriasis | 42.20 | 12.82 | 22 | 19394 | 4161 | 64475155 |
Lip swelling | 40.49 | 12.82 | 49 | 19367 | 31858 | 64447458 |
Off label use | 38.01 | 12.82 | 84 | 19332 | 632722 | 63846594 |
Drug-induced liver injury | 37.43 | 12.82 | 58 | 19358 | 47585 | 64431731 |
Dermatitis exfoliative | 36.61 | 12.82 | 28 | 19388 | 10324 | 64468992 |
Anosmia | 35.56 | 12.82 | 20 | 19396 | 4397 | 64474919 |
Photosensitivity reaction | 35.45 | 12.82 | 35 | 19381 | 18138 | 64461178 |
Oral discomfort | 34.81 | 12.82 | 25 | 19391 | 8381 | 64470935 |
Cholestasis | 34.38 | 12.82 | 54 | 19362 | 44818 | 64434498 |
Drug eruption | 34.17 | 12.82 | 48 | 19368 | 36088 | 64443228 |
Antinuclear antibody positive | 33.99 | 12.82 | 22 | 19394 | 6228 | 64473088 |
Scedosporium infection | 33.39 | 12.82 | 13 | 19403 | 1241 | 64478075 |
Urine odour abnormal | 32.76 | 12.82 | 20 | 19396 | 5116 | 64474200 |
Pityriasis rosea | 32.06 | 12.82 | 8 | 19408 | 171 | 64479145 |
Erythema nodosum | 31.88 | 12.82 | 18 | 19398 | 3986 | 64475330 |
Myalgia | 31.34 | 12.82 | 112 | 19304 | 158505 | 64320811 |
Hepatitis cholestatic | 30.64 | 12.82 | 27 | 19389 | 12128 | 64467188 |
Hepatic lesion | 30.45 | 12.82 | 20 | 19396 | 5804 | 64473512 |
Epstein-Barr virus antibody positive | 30.14 | 12.82 | 10 | 19406 | 601 | 64478715 |
Rash maculo-papular | 29.85 | 12.82 | 52 | 19364 | 46974 | 64432342 |
Blister | 29.34 | 12.82 | 71 | 19345 | 80896 | 64398420 |
Drug abuse | 29.12 | 12.82 | 3 | 19413 | 132371 | 64346945 |
Eczema | 28.88 | 12.82 | 40 | 19376 | 29680 | 64449636 |
Impetigo | 28.82 | 12.82 | 13 | 19403 | 1793 | 64477523 |
Periorbital oedema | 28.32 | 12.82 | 21 | 19395 | 7393 | 64471923 |
Skin oedema | 28.22 | 12.82 | 12 | 19404 | 1436 | 64477880 |
Red blood cell count decreased | 27.51 | 12.82 | 51 | 19365 | 48335 | 64430981 |
Hepatitis | 27.12 | 12.82 | 49 | 19367 | 45533 | 64433783 |
Dermatitis bullous | 26.89 | 12.82 | 25 | 19391 | 12029 | 64467287 |
Decreased appetite | 26.64 | 12.82 | 160 | 19256 | 281129 | 64198187 |
Swelling of eyelid | 26.41 | 12.82 | 13 | 19403 | 2179 | 64477137 |
Drug intolerance | 26.03 | 12.82 | 12 | 19404 | 187980 | 64291336 |
Abnormal faeces | 25.58 | 12.82 | 18 | 19398 | 5841 | 64473475 |
Hepatitis toxic | 25.20 | 12.82 | 16 | 19400 | 4384 | 64474932 |
Systemic lupus erythematosus rash | 25.12 | 12.82 | 11 | 19405 | 1414 | 64477902 |
Skin plaque | 24.85 | 12.82 | 21 | 19395 | 8919 | 64470397 |
Rash macular | 24.71 | 12.82 | 33 | 19383 | 23652 | 64455664 |
Rhabdomyolysis | 24.67 | 12.82 | 72 | 19344 | 91654 | 64387662 |
Face oedema | 23.57 | 12.82 | 33 | 19383 | 24728 | 64454588 |
Dermatitis | 23.38 | 12.82 | 28 | 19388 | 18001 | 64461315 |
Gastrointestinal motility disorder | 22.82 | 12.82 | 16 | 19400 | 5163 | 64474153 |
Hairy cell leukaemia | 22.66 | 12.82 | 5 | 19411 | 61 | 64479255 |
Tinea infection | 21.61 | 12.82 | 9 | 19407 | 1023 | 64478293 |
Antiphospholipid antibodies positive | 21.59 | 12.82 | 8 | 19408 | 667 | 64478649 |
Pneumonia | 21.57 | 12.82 | 91 | 19325 | 559485 | 63919831 |
Lymphocyte stimulation test positive | 21.01 | 12.82 | 9 | 19407 | 1097 | 64478219 |
Neutrophil percentage decreased | 20.92 | 12.82 | 8 | 19408 | 728 | 64478588 |
Treatment failure | 20.16 | 12.82 | 79 | 19337 | 116737 | 64362579 |
Contraindicated product administered | 20.11 | 12.82 | 4 | 19412 | 107825 | 64371491 |
Hodgkin's disease | 19.88 | 12.82 | 8 | 19408 | 833 | 64478483 |
Rash pruritic | 19.38 | 12.82 | 49 | 19367 | 57355 | 64421961 |
Maternal exposure during pregnancy | 19.09 | 12.82 | 3 | 19413 | 95881 | 64383435 |
Rash papulosquamous | 19.00 | 12.82 | 5 | 19411 | 133 | 64479183 |
Faeces pale | 18.97 | 12.82 | 11 | 19405 | 2560 | 64476756 |
Neuropsychiatric symptoms | 18.81 | 12.82 | 8 | 19408 | 958 | 64478358 |
Anal haemorrhage | 18.76 | 12.82 | 12 | 19404 | 3328 | 64475988 |
Tinea pedis | 18.42 | 12.82 | 10 | 19406 | 2051 | 64477265 |
Choluria | 18.41 | 12.82 | 6 | 19410 | 341 | 64478975 |
Stevens-Johnson syndrome | 18.10 | 12.82 | 35 | 19381 | 34214 | 64445102 |
Rash papular | 18.09 | 12.82 | 24 | 19392 | 17089 | 64462227 |
Pythium insidiosum infection | 18.03 | 12.82 | 3 | 19413 | 6 | 64479310 |
Erythrodermic psoriasis | 17.95 | 12.82 | 9 | 19407 | 1570 | 64477746 |
Malaise | 17.86 | 12.82 | 190 | 19226 | 396057 | 64083259 |
Musculoskeletal discomfort | 17.47 | 12.82 | 23 | 19393 | 16254 | 64463062 |
Biliary obstruction | 17.17 | 12.82 | 12 | 19404 | 3852 | 64475464 |
Neutrophilia | 17.13 | 12.82 | 15 | 19401 | 6679 | 64472637 |
Skin warm | 17.07 | 12.82 | 14 | 19402 | 5703 | 64473613 |
Septal panniculitis | 16.84 | 12.82 | 4 | 19412 | 69 | 64479247 |
Eosinophil count increased | 16.81 | 12.82 | 21 | 19395 | 14091 | 64465225 |
Seborrhoeic dermatitis | 16.71 | 12.82 | 9 | 19407 | 1817 | 64477499 |
Infusion related reaction | 16.63 | 12.82 | 15 | 19401 | 164452 | 64314864 |
Pustule | 16.16 | 12.82 | 8 | 19408 | 1357 | 64477959 |
Rosacea | 16.11 | 12.82 | 11 | 19405 | 3402 | 64475914 |
Mean cell volume abnormal | 15.99 | 12.82 | 6 | 19410 | 518 | 64478798 |
Weight decreased | 15.79 | 12.82 | 143 | 19273 | 285596 | 64193720 |
Cardio-respiratory arrest | 15.74 | 12.82 | 5 | 19411 | 98388 | 64380928 |
Tongue discomfort | 15.54 | 12.82 | 9 | 19407 | 2090 | 64477226 |
Vitamin E deficiency | 15.49 | 12.82 | 3 | 19413 | 18 | 64479298 |
Rheumatoid arthritis | 15.43 | 12.82 | 16 | 19400 | 164278 | 64315038 |
Erectile dysfunction | 15.38 | 12.82 | 19 | 19397 | 12608 | 64466708 |
Dehydration | 15.37 | 12.82 | 26 | 19390 | 216737 | 64262579 |
Urinary tract infection | 15.32 | 12.82 | 29 | 19387 | 231567 | 64247749 |
Myoglobin urine present | 15.30 | 12.82 | 6 | 19410 | 584 | 64478732 |
Therapeutic product effect decreased | 15.00 | 12.82 | 8 | 19408 | 115343 | 64363973 |
Intertrigo | 14.99 | 12.82 | 6 | 19410 | 616 | 64478700 |
Febrile neutropenia | 14.74 | 12.82 | 21 | 19395 | 187636 | 64291680 |
Tinea versicolour | 14.69 | 12.82 | 5 | 19411 | 325 | 64478991 |
Eye swelling | 14.61 | 12.82 | 25 | 19391 | 22256 | 64457060 |
Trichophytosis | 14.56 | 12.82 | 5 | 19411 | 334 | 64478982 |
Erythema annulare | 14.31 | 12.82 | 4 | 19412 | 134 | 64479182 |
Fungal skin infection | 14.16 | 12.82 | 12 | 19404 | 5113 | 64474203 |
Drug reaction with eosinophilia and systemic symptoms | 14.04 | 12.82 | 42 | 19374 | 54175 | 64425141 |
Prostatic haemorrhage | 14.01 | 12.82 | 4 | 19412 | 145 | 64479171 |
Respiratory gas exchange disorder | 13.79 | 12.82 | 6 | 19410 | 759 | 64478557 |
Hepatic cytolysis | 13.78 | 12.82 | 19 | 19397 | 14030 | 64465286 |
Hypokalaemia | 13.71 | 12.82 | 10 | 19406 | 121893 | 64357423 |
Deficiency of bile secretion | 13.64 | 12.82 | 3 | 19413 | 36 | 64479280 |
Intentional overdose | 13.64 | 12.82 | 5 | 19411 | 89939 | 64389377 |
Vomiting | 13.43 | 12.82 | 104 | 19312 | 551013 | 63928303 |
Dermatitis contact | 13.38 | 12.82 | 15 | 19401 | 8985 | 64470331 |
Intentional product use issue | 13.33 | 12.82 | 6 | 19410 | 95358 | 64383958 |
Laryngeal pain | 13.12 | 12.82 | 12 | 19404 | 5656 | 64473660 |
Prothrombin time shortened | 13.02 | 12.82 | 9 | 19407 | 2840 | 64476476 |
Fall | 13.01 | 12.82 | 73 | 19343 | 416753 | 64062563 |
Pulmonary embolism | 12.92 | 12.82 | 15 | 19401 | 146341 | 64332975 |
None
Source | Code | Description |
---|---|---|
ATC | D01AE15 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
ATC | D01BA02 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR SYSTEMIC USE Antifungals for systemic use |
FDA CS | M0000751 | Allylamine |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
CHEBI has role | CHEBI:50183 | P450 inhibitors |
CHEBI has role | CHEBI:59285 | squalene monooxygenase inhibitors |
CHEBI has role | CHEBI:83317 | sterol biosynthesis inhibitors |
FDA EPC | N0000175874 | Allylamine Antifungal |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea capitis | indication | 5441008 | |
Tinea pedis | indication | 6020002 | DOID:12403 |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Tinea corporis | indication | 84849002 | |
Tinea cruris | indication | 399029005 | |
Onychomycosis due to dermatophyte | indication | 402134005 | |
Onychomycosis of fingernails | indication | 403058003 | |
Onychomycosis of toenails | indication | 403059006 | |
Candidiasis of skin | off-label use | 49883006 | |
Chromoblastomycosis | off-label use | 187079000 | |
Alcoholism | contraindication | 7200002 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Breastfeeding (mother) | contraindication | 413712001 |
Species | Use | Relation |
---|---|---|
Dogs | Otitis externa caused by yeast, Malassezia pachydermatis | Indication |
Product | Applicant | Ingredients |
---|---|---|
Osurnia | Dechra, Ltd. | 3 |
CLARO | Elanco US Inc. | 3 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.02 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.63 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.39 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
Squalene monooxygenase | Enzyme | Ki | 7.52 | CHEMBL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.67 | DRUG MATRIX | |||||
Squalene epoxidase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 7.66 | DRUG MATRIX | |||||
Squalene monooxygenase | Enzyme | IC50 | 4.03 | CHEMBL |
ID | Source |
---|---|
4023600 | VUID |
N0000021605 | NUI |
D02219 | KEGG_DRUG |
78628-80-5 | SECONDARY_CAS_RN |
4020792 | VANDF |
4023600 | VANDF |
C0076110 | UMLSCUI |
CHEBI:9448 | CHEBI |
CHEMBL822 | ChEMBL_ID |
DB00857 | DRUGBANK_ID |
CHEMBL1200832 | ChEMBL_ID |
D000077291 | MESH_DESCRIPTOR_UI |
1549008 | PUBCHEM_CID |
5657 | INN_ID |
G7RIW8S0XP | UNII |
235838 | RXNORM |
116863 | MMSL |
5547 | MMSL |
d04012 | MMSL |
004051 | NDDF |
004052 | NDDF |
108925005 | SNOMEDCT_US |
108927002 | SNOMEDCT_US |
373450007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
LamisilAT Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0067-3999 | CREAM | 10 mg | TOPICAL | NDA | 13 sections |
LAMISILAT | HUMAN OTC DRUG LABEL | 1 | 0067-6296 | AEROSOL, SPRAY | 0.84 g | TOPICAL | NDA | 13 sections |
LAMISILAT | HUMAN OTC DRUG LABEL | 1 | 0067-6297 | AEROSOL, SPRAY | 0.84 g | TOPICAL | NDA | 13 sections |
Lamisil AT | HUMAN OTC DRUG LABEL | 1 | 0067-8100 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Lamisil ATfor Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0067-8114 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Walgreens Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 0363-2080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Terbinafine Hydrochloride | HUMAN OTC DRUG LABEL | 1 | 0363-2083 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 11673-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
athletes foot | HUMAN OTC DRUG LABEL | 1 | 11673-401 | CREAM | 10 mg | TOPICAL | NDA | 7 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 11822-0080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Terbinafine | Human Prescription Drug Label | 1 | 16714-795 | TABLET | 250 mg | ORAL | ANDA | 27 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 21130-080 | CREAM | 1 g | TOPICAL | ANDA | 13 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-630 | TABLET | 250 mg | ORAL | ANDA | 19 sections |
Good Neighbor Pharmacy | HUMAN OTC DRUG LABEL | 1 | 24385-524 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Kroger Antifungal | HUMAN OTC DRUG LABEL | 1 | 30142-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-209 | TABLET | 250 1 | ORAL | ANDA | 26 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 36800-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Shopko Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 37012-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 37808-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
athletes foot | HUMAN OTC DRUG LABEL | 1 | 41163-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
ShopRite | HUMAN OTC DRUG LABEL | 1 | 41190-083 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Antifungal | HUMAN OTC DRUG LABEL | 1 | 41250-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Antifungal Foot | HUMAN OTC DRUG LABEL | 1 | 41520-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
terbinafine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42043-410 | TABLET | 250 mg | ORAL | ANDA | 20 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-598 | TABLET | 250 mg | ORAL | ANDA | 31 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-906 | TABLET | 250 mg | ORAL | ANDA | 33 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-893 | TABLET | 250 mg | ORAL | ANDA | 31 sections |
equate Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 49035-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 49348-790 | CREAM | 1 g | TOPICAL | ANDA | 13 sections |
Silka Antifungal | HUMAN OTC DRUG LABEL | 1 | 50066-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |